US2019374511A1PendingUtilityA1
Oxymetazoline for the treatment of ano-rectal disorders
Est. expiryApr 26, 2031(~4.8 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 1/00A61P 21/00A61K 9/0031A61K 31/4164A61K 31/4174A61K 45/06A61K 31/485A61K 31/451
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method,
wherein the method treats fecal incontinence in a subject in need thereof, wherein the method comprises: administering a therapeutically effective amount of a composition comprising oxymetazoline or a pharmaceutically acceptable salt thereof to the subject's anal cavity, to treat the fecal incontinence, wherein the therapeutically effective amount of the composition comprises 0.1% to 1% of oxymetazoline or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the composition comprises oxymetazoline hydrochloride.
3 . The method of claim 1 , wherein the composition further comprises at least one carrier, diluent, excipient, or combinations thereof.
4 . The method of claim 1 , wherein the composition is selected from the group consisting of:
long acting, controlled release, slow release, sustained release, bioadhesive and mucoadhesive.
5 . The method of claim 1 , wherein the composition is in a dosage form selected from the group consisting of: gel, cream, paste, spray suppository, mousse, emollient, powder, solution, suspension and foam.
6 . The method of claim 1 , wherein the therapeutically effective amount of the composition comprises 0.08% to 0.8% of oxymetazoline or a pharmaceutically acceptable salt thereof.
7 . The method of claim 1 , wherein the therapeutically effective amount of the composition comprising oxymetazoline or a pharmaceutically acceptable salt thereof is sufficient to treat fecal incontinence in the subject for at least 4 hours.Join the waitlist — get patent alerts
Track US2019374511A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.